Mabthera 100mg (Rituximab 100mg Injection)
MabThera (Rituximab)belongs to a group of cancer drugs known as monoclonal antibodies|.
Monoclonal antibodies recognise and lock onto specific proteins on the surface of cancer cells. This helps the body’s immune system to recognise the cancer cells and destroy them. Monoclonal antibodies are sometimes called targeted therapies because they target cancer cells.
Mabthera (Rituximab 100mg Injection) works
MabThera (Rituximab) locks onto a protein called CD20, which is found on the surface of white blood cells called B-lymphocytes or B-cells. This triggers the body’s immune system to attack the cells and destroy them.
As well as being found on the surface of normal B-cells, CD20 is also present on most of the abnormal B-cells which occur in many types of non‑Hodgkin lymphoma and on some of the abnormal B-cells found in CLL.
MabThera (Rituximab) destroys both abnormal (malignant) and normal B-cells. However, the body can replace normal B-cells that are damaged so their numbers recover once treatment is over.
When it is used
MabThera (Rituximab) is used to treat several types of non‑Hodgkin lymphoma. It may also be used to treat chronic lymphocytic leukaemia. It is often given in combination with chemotherapy| but may be given on its own.
MabThera (Rituximab)may also be given to people with follicular lymphoma| who have no signs of cancer at the end of their treatment (remission). The aim is to keep the lymphoma away for as long as possible.This is called maintenance therapy and is given every three months, for up to two years.
MabThera is indicated in adults for the following indications: Non-Hodgkin’s lymphoma (NHL)MabThera is indicated for the treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy. MabThera maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy. MabThera monotherapy is indicated for treatment of patients with stage III-IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. MabThera is indicated for the treatment of patients with CD20 positive diffuse large B cell non-Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.